Skip to content

TriangleGet started

← Full study record

NCT04162210 · OUTCOME

Observed Plasma Concentrations of Belantamab Mafodotin- Total Monoclonal Antibody (mAb)

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: ug/mL
Interval / dispersion: Standard Deviation
Time frame: Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; SOI + 24h on D1&2 of C1&3; D4, D8-15, D22 of C1&3; D1of C2,3,4 & 6; D2 of C3; and EOT (~242 weeks)

What was measured

Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

Analysis population: Pharmacokinetic population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points.

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	217

Reported measurements

C1 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	203

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.5379	5.58667	Not reported	Not reported	Not reported

C1 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	201

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	44.2483	14.91713	Not reported	Not reported	Not reported

C1 D1, SOI + 24 hours

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	102

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	41.2999	14.01003	Not reported	Not reported	Not reported

C1 D2, SOI+ 24 hours

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	202

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	32.7096	11.17415	Not reported	Not reported	Not reported

C1 D4

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	111

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	20.9259	8.82782	Not reported	Not reported	Not reported

C1 D8-15

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	112

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	12.2688	6.20180	Not reported	Not reported	Not reported

C1 D22

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	23

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	5.9391	4.89415	Not reported	Not reported	Not reported

C2 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	32.0000	28.37622	Not reported	Not reported	Not reported

C2 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	186

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	6.2446	5.39820	Not reported	Not reported	Not reported

C2 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	184

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	51.3993	21.28458	Not reported	Not reported	Not reported

C3 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	29.8917	25.68839	Not reported	Not reported	Not reported

C3 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	143

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	10.4384	8.69143	Not reported	Not reported	Not reported

C3 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	144

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	54.5050	22.63257	Not reported	Not reported	Not reported

C3 D1, SOI + 24 hours

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	74

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	48.7361	20.09005	Not reported	Not reported	Not reported

C3 D2

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	50.3500	0.49497	Not reported	Not reported	Not reported

C3 D2, SOI + 24 hours

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	123

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	44.6118	15.68169	Not reported	Not reported	Not reported

C3 D4

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	69

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	33.1541	14.83313	Not reported	Not reported	Not reported

C3 D8-15

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	68

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	23.7107	11.14934	Not reported	Not reported	Not reported

C3 D22

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	14

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13.0207	8.94586	Not reported	Not reported	Not reported

C4 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	41.2000	31.11270	Not reported	Not reported	Not reported

C4 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	121

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13.1691	10.19527	Not reported	Not reported	Not reported

C4 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	118

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	57.9805	20.36662	Not reported	Not reported	Not reported

C6 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	1

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	77.3000	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

C6 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	88

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	14.8742	9.94411	Not reported	Not reported	Not reported

C6 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	90

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	57.0211	32.13534	Not reported	Not reported	Not reported

C9 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	63

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	16.1902	10.42646	Not reported	Not reported	Not reported

C12 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	44

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	18.3373	12.66464	Not reported	Not reported	Not reported

C18 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	25

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	24.4376	15.48838	Not reported	Not reported	Not reported

C24 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	14

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	21.7079	12.62491	Not reported	Not reported	Not reported

C30 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	6

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	19.8650	14.43844	Not reported	Not reported	Not reported

C36 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	24.3000	21.96383	Not reported	Not reported	Not reported

C42 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	1

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	4.5600	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

EOT (~242 weeks)

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	127

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	8.3097	9.58575	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
5.58667
value
0.5379
denoms
counts
group Id
OG000
value
203
units
Participants
title
C1 D1, Pre-dose
categories
measurements
group Id
OG000
spread
14.91713
value
44.2483
denoms
counts
group Id
OG000
value
201
units
Participants
title
C1 D1, EOI
categories
measurements
group Id
OG000
spread
14.01003
value
41.2999
denoms
counts
group Id
OG000
value
102
units
Participants
title
C1 D1, SOI + 24 hours
categories
measurements
group Id
OG000
spread
11.17415
value
32.7096
denoms
counts
group Id
OG000
value
202
units
Participants
title
C1 D2, SOI+ 24 hours
categories
measurements
group Id
OG000
spread
8.82782
value
20.9259
denoms
counts
group Id
OG000
value
111
units
Participants
title
C1 D4
categories
measurements
group Id
OG000
spread
6.20180
value
12.2688
denoms
counts
group Id
OG000
value
112
units
Participants
title
C1 D8-15
categories
measurements
group Id
OG000
spread
4.89415
value
5.9391
denoms
counts
group Id
OG000
value
23
units
Participants
title
C1 D22
categories
measurements
group Id
OG000
spread
28.37622
value
32.0000
denoms
counts
group Id
OG000
value
3
units
Participants
title
C2 D1
categories
measurements
group Id
OG000
spread
5.39820
value
6.2446
denoms
counts
group Id
OG000
value
186
units
Participants
title
C2 D1, Pre-dose
categories
measurements
group Id
OG000
spread
21.28458
value
51.3993
denoms
counts
group Id
OG000
value
184
units
Participants
title
C2 D1, EOI
categories
measurements
group Id
OG000
spread
25.68839
value
29.8917
denoms
counts
group Id
OG000
value
18
units
Participants
title
C3 D1
categories
measurements
group Id
OG000
spread
8.69143
value
10.4384
denoms
counts
group Id
OG000
value
143
units
Participants
title
C3 D1, Pre-dose

denoms

counts
group Id
OG000
value
217
units
Participants

description

Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

dispersion Type

Standard Deviation

groups

description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin

param Type

MEAN

population Description

Pharmacokinetic population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points.

reporting Status

POSTED

time Frame

Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; SOI + 24h on D1&2 of C1&3; D4, D8-15, D22 of C1&3; D1of C2,3,4 & 6; D2 of C3; and EOT (~242 weeks)

title

Observed Plasma Concentrations of Belantamab Mafodotin- Total Monoclonal Antibody (mAb)

type

SECONDARY

unit Of Measure

ug/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice